Our Team
The Thera4Care consortium represents a diverse and dynamic alliance of 29 partners dedicated to pioneering advancements in healthcare. Coordinated by the Università Cattolica del Sacro Cuore in Rome, Policlinico Universitario Fondazione Agostino Gemelli, GE Healthcare, and Essen University Hospital, our consortium blends the expertise of universities, research institutions, industry, public bodies, non-profit groups, and small to medium-sized enterprises. The logos below represent the various esteemed members of our consortium, showcasing the breadth of collaboration and expertise involved in the Thera4Care project.
Academic Coordinator
Università Cattolica del Sacro Cuore is a leading Italian university with a prestigious Faculty of Medicine and Surgery based in Rome. The Department of Diagnostic Imaging and Radiotherapy integrates radiology, nuclear medicine, and radiotherapy, focusing on personalised and multidisciplinary care. Nuclear Medicine plays a vital role, advancing theranostics and radiopharmaceutical research, particularly in oncology. The university promotes technological innovation, ethical values, and human-centered education, preparing future healthcare professionals to meet the challenges of modern medicine.
Industry Coordinator
GE HealthCare, as a leading global medical technology, pharmaceutical diagnostics, and digital solutions provider sees possibilities through innovation. Therefore, GE HealthCare is proud to take on the key industrial role in Thera4Care to advance connected, personalised, and compassionate cancer care as well as to improve healthcare system readiness for precision medicine.
Within Thera4Care, GE HealthCare focusses on:
-
Supply & Production (WP4) - expanding the European network of copper producing isotope good manufacturing practices (GMP) sites by implementing a unified hardware and software platform, ensuring identical and reproducible production methods.
-
AI (WP6) - building AI-enabled imaging and multi-modal theranostic clinical decision support systems with predictive analytics capabilities to ensure optimized patient outcomes.
-
Precision Imaging (WP8) - developing next-generation SPECT-CT imaging scanners to enable imaging with a wide range of alpha emitters.
The Clinic of Nuclear Medicine at University Hospital Essen is equipped with state-of-the-art imaging technologies, including PET/CT, PET/MRI, and SPECT/CT systems. As the second largest nuclear medicine facility in Germany, the clinic performs over 10,000 PET/CT examinations and 1,800 inpatient radionuclide therapies annually. Our main research focus lies in the clinical translation of novel theranostic approaches, encompassing first-in-human, Phase I, Phase II, and Phase III clinical trials.
Within Thera4Care, University Hospital Essen contributes to:
-
Regulatory (WP2) - leveraging its extensive experience with clinical trials and dossier preparation to support clinical trial authorisation under Regulation (EU) No. 536/2014, and cooperating with national medicines agencies to ensure compliance with local regulations.
-
Preclinical Research (WP3) - developing relevant cancer models and novel FAP- based theranostic radioligands to advance targeted radionuclide therapy.
-
Clinical Trials (WP5) - initiating a Phase I/II clinical trial to investigate the therapeutic radioligand ¹⁶¹Tb- FAP.
-
AI (WP6) - developing an AI algorithm for the automated extraction of imaging biomarkers to provide insights into patient’s biological condition as well as training developed algorithms for the detection of new personalized treatment options.
-
Precision Imaging (WP8) - developing and validating next generation digital SPECT/CT systems capable of detecting alpha-emitting radionuclides in patients.
Collaborate Project Management possesses extensive expertise in project management and administration. Within Thera4Care, they are mainly involved in Project Management (WP1), which focuses on enhancing internal communications and active collaboration with stakeholders, crucial for enriching project outcomes and achieving strategic objectives. Additionally, they co-lead Training & Dissemination (WP9), where they oversee and direct activities related to communication and dissemination.
The Institut Jules Bordet (JBI) is a fully integrated, multidisciplinary centre dedicated to cancer care. Unique in Belgium and internationally renowned, the hospital has been at the forefront of oncology for over 75 years. Our teams provide patients with leading-edge diagnostic and therapeutic strategies in the prevention, screening, and active treatment of all cancer types. JBI is also a hub for cancer research, as well as a provider of specialised academic training.
Within Thera4Care, JBI plays a central role in both preclinical and clinical research. The institute leads and contributes to Preclinical Research (WP3) through the validation of innovative radiopharmaceuticals via in vitro and in vivo studies. JBI also leads Dosimetry (WP7) and co-leads AI (WP6) activities, with the aim of improving the personalisation of radioligand therapies, particularly those based on Lutetium-177 PSMA, with the broader objectives of enhancing patient stratification and improving treatment efficacy across Europe.
The Hospital General Universitario Gregorio Marañón is one of the largest and most prestigious hospitals in Spain. Its Nuclear Medicine Department is a nationally and internationally recognised reference centre, with over 60 years of experience in diagnostic imaging and radiometabolic therapies. The department performs all radiopharmaceutical treatments currently approved in Spain, carrying out more than 15,000 diagnostic and therapeutic procedures each year. These include PET/CT scans, gamma imaging, radionuclide therapies, and personalised dosimetry protocols. It not only serves its own institution but also supports a broad network of hospitals and healthcare centres throughout the Madrid region.
As part of Thera4Care, the hospital brings extensive expertise in the use of radiopharmaceuticals and targeted therapies. Its main contribution lies in AI (WP6) and Precision Imaging (WP8), where it contributes to the clinical validation of novel theragnostic agents, advances the implementation of personalised dosimetry protocols, and integrates AI to optimise diagnosis and treatment planning.
Erasmus MC plays a leading role in the advancement of theranostics. Both In-111-Octreotide (Octreoscan®) and Lu-177-DOTATATE originated from this centre, reflecting its longstanding contribution to the field. Erasmus MC has a rich history in nuclear medicine, with extensive experience in treating patients using Lu-177-labelled compounds, and in the development of radiometal-based therapeutics and dosimetry. The entire translational process, from bench to bedside, is deeply embedded within the institution.
Within Thera4Care, Erasmus MC involvement in Dosimetry (WP7) and Precision Imaging (WP8) will further strengthen the project through its recognised expertise in dosimetry, nuclear medicine physics, and clinical nuclear medicine.
The Institut de Cancérologie de l’Ouest (ICO) is a leading French cancer centre contributing actively to Thera4Care’s Preclinical Research (WP3), AI (WP5), Dosimetry (WP7), and Training & Dissemination (WP9) activities, drawing on its recognised expertise in both preclinical and early-phase clinical research.
ICO develops in vitro and in vivo sarcoma models specifically designed for radiopharmaceutical investigation, enabling precise evaluation of theranostic agents. Clinically, ICO has a strong track record in early-phase nuclear medicine trials and personalised dosimetry. The institute also provides a rich imaging dataset (PET and SPECT/CT) to support AI-driven tools and conducts health economic modelling to evaluate the long-term cost-effectiveness of novel radiotherapeutic strategies across Europe.
The European Association of Nuclear Medicine (EANM) is Europe’s largest non-profit organisation in nuclear medicine, representing the field to European and international institutions. EANM advances public health through innovation, education, and collaboration, supporting workforce development and knowledge exchange.
As part of Thera4Care, EANM contributes to Regulatory (WP2) and Training & Dissemination (WP9). A dedicated online platform will be created, drawing on EANM’s expertise and ERASMUS+ curriculum content to support high-quality, accessible education in nuclear medicine across Europe and beyond.
With over 70 years of experience in nuclear research and technology, SCK CEN is one of Belgium’s largest research institutions. Our research focuses on three key areas: innovative nuclear systems, nuclear waste management and dismantling, and the fight against cancer. To fight cancer, we are strengthening our role in nuclear medicine. While we continue to produce medical radioisotopes, our scope now extends to preclinical research and the pilot production of novel radiopharmaceuticals.
Within Thera4Care, SCK CEN is helping to shape the future of precision oncology by leading Preclinical Research (WP3). This includes the development of cancer models, evaluation of imaging and therapeutic efficacy, as well as optimisation of treatment strategies.
Scientific Coordinator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG) is the largest private hospital in Italy and operates as a non-profit foundation under private law. Founded in 1964, it serves as the teaching hospital for the School of Medicine at Università Cattolica del Sacro Cuore (UCSC). FPG is a leading healthcare and research institution in Italy, with recognised expertise in cancer treatment, genomics and precision medicine, patient-centered care, and digital health.
As part of Thera4Care, FPG serves as the Scientific Coordinator and leads Project Management (WP1), Regulatory (WP2), AI (WP6), and Training & Dissemination (WP9) activities. It also collaborates on Preclinical Research (WP3) and Clinical Trials (WP5), having recently acquired a microCT, microPET, and microSPECT to support its contributions.
The Oncidium Foundation is a nonprofit organisation dedicated to advancing radiotheranostics in cancer care through three pillars: Education, Access, and Hope. Education is at the heart of our mission. By providing accurate, up-to-date, and accessible information, we help patients and healthcare professionals in understanding how these therapies work and their effectiveness across cancer types. This knowledge leads to more personalised care and better outcomes.
We tailor educational resources to meet the specific needs of each audience, empowering informed decision-making at every step. Within Training & Dissemination (WP9) activity of Thera4Care, we work to bring knowledge, support, and hope to those facing cancer worldwide.
Datawizard is a digital health consultancy boasting over 20 years of experience in healthcare IT-based innovation, including telemedicine, mHealth applications and healthcare information systems. Our work contributes to empowering patients and improving standards of care.
As part of the Thera4Care Training & Dissemination (WP9) activity, Datawizard is responsible for the design and development of the Educational Platform for patients, drawing on expertise in digital learning, patient engagement, and UX design to enhance health literacy and adherence to care pathways. The company also supports stakeholder engagement and contributes to the project business modelling activities
Curasight is a clinical stage biotech company committed to improving both diagnosis and the treatment of certain types of cancer. Utilising its cutting-edge uPAR Theranostic radionuclide platform the company is able to more accurately characterise the type and stage of the tumor using intelligent cancer imaging (uTRACE®) and with that knowledge, develop a more targeted, gentle and efficient approach to treatment (uTREAT®). The company was founded on a strong understanding of nuclear medicines, based on 10 years of research at Copenhagen’s University hospital, Rigshospitalet. Led by science and industry experts Curasight has built a pipeline of products which have been tested to Phase 2 of clinical development and which are robustly patent protected. Located in Copenhagen, Denmark, the company has strong international partnerships both in academia and industry and is firmly committed to using its pioneering technology to improve the lives of cancer patients globally.
Minerva Imaging is a scientifically driven CRO and CDMO specialised in targeted radionuclide therapies. The company focuses on the use of advanced models in oncology, cardiovascular diseases, and in vivo molecular imaging to support translational research and drug development. Minerva Imaging works closely with its clients to understand their scientific questions and explore how its methods and capabilities can provide effective answers.
Its facility in Denmark offers best-in-industry, fully integrated radiopharmaceutical research, drug development, and manufacturing services, contributing to the Thera4Care Preclinical Research (WP3) and Supply & Production (WP4) activities.
EXINI Diagnostics develops and distributes advanced AI-driven Software as a Medical Device (SaMD) and imaging biomarkers for clinical use in nuclear medicine. The company also provides a comprehensive data management platform designed to support large-scale medical imaging trials, research, and analytics.
Founded in 1999 as a spin-off from a research group at Lund University, EXINI has since brought a range of clinical solutions to market, including applications for cardiac, neuro, bone scans, and PSMA imaging. With our vast experience in the field,
EXINI contributes to Thera4Care AI (WP6), advancing AI-driven quantification, disease monitoring, and tracking. We also empower participating centres to securely share data within a structured and compliant environment.
Aiforia is a trusted provider of deep learning AI solutions for digital pathology. Aiforia’s solutions enhance the speed, accuracy, and consistency of analysing large and complex medical images, aiming to enable better care for each patient. With thousands of AI models already developed on the Aiforia® Platform for research purposes, and several diagnostic solutions deployed, Aiforia is significantly impacting pathology and healthcare.
Within Thera4care, Aiforia contributes to AI (WP6) by developing of robust, AI-powered image analysis solutions for supporting clinical decision-making and predictive modelling – both essential to advancing personalised medicine.
Atley Solutions is the global leader in manufacturing solutions for Astatine-211 (At-211) radiopharmaceuticals, driving innovation in targeted alpha therapy for cancer treatment. As leader of the Astatine track within Thera4Care, Atley is driving the standardisation and scale-up of At-211 production across Europe. Its flagship platform, the Atley C100, is the world’s first GMP-compliant automated module for producing At-211 radiopharmaceuticals.
Through strategic partnerships and deep technical expertise, Atley plays a pivotal role in Thera4Care’s Supply & Production (WP4) contributing to unlocking the full therapeutic potential of precision radiopharmaceuticals and delivering next-generation cancer treatments to patients across Europe.
Founded in 2002 as a spin-off between Gustave Roussy and the Curie Institute, DOSIsoft is a market leader specialising in dosimetry software for Radiation Oncology and Nuclear Medicine to improve cancer patient safety and treatment quality. DOSIsoft delivers highly competitive, patient-specific quality assurance and medical imaging solutions, currently deployed in over 600 hospital centres across 60 countries.
Within Thera4Care, DOSIsoft plays a key role in Dosimetry (WP 7), contributing to the improvement of clinical outcomes through AI-based imaging and personalised dosing protocols. Drawing on over 20 years of technological innovation and deep expertise in dosimetry, DOSIsoft is advancing novel dosimetric concepts to streamline and improve clinical workflows.
TerThera is a radionuclide production-focused company based in The Netherlands. The founders and staff of TerThera have decades of experience in the nuclear medicine industry and are highly dedicated to bringing the innovative radionuclide Terbium-161 (Tb-161) to the clinic. TerThera is building a global platform including GMP production facilities in Europe, USA and Asia to meet the growing demand for radionuclides in RLT.
Within Thera4Care, we contribute to Supply & Production (WP4) as a supplier of Terbium-161 throughout the course of the project.
Syreon Research Institute is an independent research institute in Budapest, providing expert services since 2008 in the fields of evidence synthesis, health economics, health policy, health technology assessment (HTA), public health, as well as food and nutrition science. Syreon aims to apply scientific evidence and health economic knowledge in practice to maximise health gains for society.
The Institute collaborates with an elite portfolio of global pharmaceutical corporations, emerging biotechnology companies, public health institutes, and academic networks. It also provides training for public healthcare institutes, as well as the pharmaceutical and health services sectors.
As the leader of Training & Dissemination (WP9) within Thera4Care, Syreon is developing a Conceptual Value Framework and cost-effectiveness models to evaluate the long-term impact of theranostic innovations in ovarian, pancreatic, and sarcoma cancers.
Perspective Therapeutics, Inc. (CATX) is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. CATX has proprietary technology that utilises the alpha-emitting isotope ²¹²Pb to deliver powerful radiation directly to cancer cells via specialised targeting moieties. CATX is also developing complementary imaging diagnostics that incorporate the same targeting moieties, providing the opportunity to personalise treatment and optimise patient outcomes. This “theranostic” approach enables the ability to see specific tumours and then treat them to potentially improve efficacy and minimise toxicity.
CATX’s melanoma (VMT01), neuroendocrine tumour (VMT-α-NET) and solid tumour (PSV359) programmes are in Phase 1/2a imaging and therapy trials in the U.S. CATX is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary ²¹²Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
The University of Gothenburg excels in theranostics by integrating precision radionuclide imaging with alpha-particle therapy for metastatic cancer. Their multidisciplinary team develops astatine-211–labelled compounds, including radioimmunoconjugates, small molecules, and pretargeting systems, while advancing astatine-211 chemistry and metrology. They study pharmacokinetics, dosimetry, and biodistribution, and assess therapeutic efficacy in ovarian cancer models using their in-house–developed alpha camera. A phase I “first-in-man” clinical trial with ²¹¹At-MX35 F(ab')₂, delivered intraperitoneally and monitored with SPECT imaging, demonstrated safety and targeted uptake in twelve ovarian cancer patients. This combined expertise contributes to the Thera4Care initiative focused on astatine-211-based theranostics.
.png)
PSI is Switzerland's largest research institute for natural sciences and engineering and the central hub for its major research facilities. As part of the ETH Domain, PSI is a key pillar of Swiss science, advancing cutting-edge research in future technologies, energy and climate, health innovation, and fundamental science. Its unique large research facilities are available to both academia and industry, attracting researchers from around the world every year to perform measurements.
Within Thera4Care, PSI contributes to both Preclinical Research (WP3) and Supply & Production (WP4), leading the development of medical radionuclides, which are studied on site in the preclinical setting. The manufacturing of innovative radiopharmaceuticals for clinical translation is also part of PSI’s capabilities in enabling translational research in radiopharmaceutical sciences.
Semmelweis University is a leading institution of higher education in Hungary and the Central European region within the area of medicine and health sciences. Its main commitment is the integrity of education, research and healing, which makes the more than 250-year-old Semmelweis University an internationally recognised center of knowledge. As a specialist university, it holds a unique place within the country.
In addition to teaching, Semmelweis University is the largest provider of health care services in Hungary. Even though practical teaching takes place at the university’s clinics and hospitals, they provide the highest quality patient care services at the same time. Most of the departments cater for the most serious cases and patients requiring complex treatment, thus making the university a national health care provider.
Heading 1
.png)
